导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 19.40% | 35/354 |
| 近一周 | -1.89% | 93/362 |
| 近一月 | -2.50% | 127/362 |
| 近一季 | -0.86% | 123/362 |
| 近半年 | 27.08% | 10/358 |
| 近一年 | 24.15% | 47/349 |
| 近两年 | 54.88% | 31/314 |
| 近三年 | 113.81% | 7/246 |
| 成立以来 | 440.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.49% 253/360 |
29.50% 16/366 |
- - |
- - |
| 2025 | 21.57% 102/358 |
-12.21% 321/340 |
22.23% 7/348 |
11.88% 130/354 |
1.25% 94/358 |
| 2024 | 30.44% 16/329 |
11.58% 30/280 |
11.48% 16/310 |
0.91% 232/318 |
3.92% 99/329 |
| 2023 | 52.31% 16/275 |
19.86% 5/205 |
15.98% 31/230 |
-5.84% 172/262 |
16.36% 5/276 |
| 2022 | -28.11% 133/201 |
-8.15% 53/153 |
-19.62% 139/164 |
-6.33% 85/189 |
3.96% 141/202 |
| 2021 | 30.90% 16/150 |
1.63% 153/312 |
10.60% 56/328 |
1.01% 51/358 |
15.30% 1/151 |
| 2020 | 37.74% 14/103 |
-13.14% 160/280 |
28.63% 47/295 |
11.11% 42/299 |
10.95% 109/305 |
| 2019 | 45.61% 2/88 |
18.46% 24/258 |
5.69% 30/267 |
2.78% 75/253 |
13.14% 23/266 |
| 2018 | -2.27% 27/79 |
- - |
- - |
7.53% 32/225 |
-16.64% 184/241 |
| 2017 | 28.54% 14/69 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2946 | 31.47% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3488 | 29.79% |
| 汇添富恒生生物科技ETF(QDII) | 1.1245 | 29.24% |
| 南方恒生生物科技ETF(QDII) | 1.1400 | 29.08% |
| 广发道琼斯石油指数美元现汇A | 0.4638 | 27.44% |
| 广发道琼斯石油指数美元现汇C | 0.4557 | 27.38% |
| 广发道琼斯石油指数(QDII-LOF)美元现汇E | 0.4568 | 27.33% |
| 南方恒生生物科技ETF发起联接(QDII)A | 1.2646 | 27.30% |
| 华夏恒生生物科技ETF发起式联接(QDII)C | 1.1472 | 27.25% |
| 汇添富恒生生物科技ETF发起式联接(QDII)C | 1.6358 | 27.22% |
| 易方达标普信息科技指数(QDII-LOF)A(美元现汇) VS. 建信富时100指数(QDII)人民币A(539003) |